​

TScan Therapeutics Ownership | Who Owns TScan Therapeutics?

OverviewForecastRevenueFinancialsChart

TScan Therapeutics Ownership Summary

TScan Therapeutics is owned by 26.67% institutional investors, 0.23% insiders, and 73.10% retail investors. Lynx1 capital management lp is the largest institutional shareholder, holding 6.06% of TCRX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.36% of its assets in TScan Therapeutics shares.

TCRX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTScan Therapeutics26.67%0.23%73.10%
SectorHealthcare Stocks 41.87%10.80%47.33%
IndustryBiotech Stocks 43.97%10.75%45.28%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Lynx1 capital management lp7.86M6.06%$14.30M
Blackrock4.46M4.70%$26.10M
Ecor1 capital5.00M4.21%$15.20M
Bvf inc/il5.23M4.03%$9.51M
Baker bros. advisors lp2.78M2.15%$5.07M
Blackrock funding, inc. /de2.38M1.84%$4.34M
Vanguard group2.32M1.79%$4.22M
Propel bio management1.93M1.49%$3.52M
Abrdn1.35M1.04%$2.47M
Deer management1.25M0.96%$2.27M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Dc funds, lp630.00K36.87%$1.15M
Propel bio management1.93M3.52%$3.52M
Lynx1 capital management lp7.86M2.91%$14.30M
Ecor1 capital5.00M0.57%$15.20M
Bvf inc/il5.23M0.39%$9.51M
Deer management1.25M0.20%$2.27M
Militia capital partners, lp102.10K0.09%$185.82K
Alphabet1.08M0.08%$1.96M
Tang capital management600.00K0.04%$1.09M
Baker bros. advisors lp2.78M0.04%$5.07M

Top Buyers

HolderShares% AssetsChange
Blackrock4.46M0.00%2.76M
Abrdn1.35M0.00%463.37K
Vanguard group2.32M0.00%168.54K
Citadel advisors157.96K0.00%146.53K
Two sigma advisers, lp288.80K0.00%74.40K

Top Sellers

HolderShares% AssetsChange
Adage capital partners gp---3.50M
Checkpoint capital---2.02M
Great point partners---1.02M
Stempoint capital lp---860.95K
Ubs group11.07K--389.33K

New Positions

HolderShares% AssetsChangeValue
Voleon capital management lp47.88K0.00%47.88K$87.14K
Lpl financial21.50K-21.50K$39.13K
Xtx topco17.63K0.00%17.63K$32.08K
Rockefeller capital management200.00-200.00$364.00

Sold Out

HolderChange
Ifp advisors-7.00
Rothschild investment-110.00
Gamma investing-142.00
Corecap advisors-166.00
Sterling capital management-259.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202572-4.00%34,601,2331.17%263.84%25-41.86%2864.71%
Jun 30, 202578-12.36%35,711,883-7.86%273.08%46-6.12%17-5.56%
Mar 31, 2025924.55%40,135,892-3.36%302.53%506.38%1918.75%
Dec 31, 202427-68.60%11,233,656-73.15%90.76%13-71.11%5-68.75%
Sep 30, 20248610.26%41,835,4450.96%351.85%45-8.16%1623.08%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.34M2.36%-29.61K
Simplify Propel Opportunities ETF1.05M1.84%-
BlackRock Health Sciences Opps Inv A650.52K1.15%-
BlackRock Health Sciences Term Trust609.80K1.07%-435.97K
abrdn Life Sciences Investors532.24K0.94%138.80K
Invesco Dorsey Wright SmallCap Momt ETF475.53K0.90%-
Vanguard Institutional Extnd Mkt Idx Tr500.00K0.88%-206.08K
abrdn Healthcare Investors498.01K0.88%-
Fidelity Small Cap Index392.73K0.69%-
Fidelity Extended Market Index281.05K0.50%-2.31K

Recent Insider Transactions

DateNameRoleActivityValue
May 19, 2025Lynx1 Capital Management LP-Buy$1.67M
May 20, 2025Lynx1 Capital Management LP-Buy$1.44M
Dec 26, 2024Lynx1 Capital Management LP-Buy$750.00
Dec 13, 2024Lynx1 Capital Management LP-Buy$290.14K
Dec 12, 2024Lynx1 Capital Management LP-Buy$95.63K

Insider Transactions Trends

DateBuySell
2025 Q22-
2025 Q1--
2024 Q44-
2024 Q331
2024 Q23-

TCRX Ownership FAQ

Who Owns TScan Therapeutics?

TScan Therapeutics shareholders are primarily institutional investors at 26.67%, followed by 0.23% insiders and 73.10% retail investors. The average institutional ownership in TScan Therapeutics's industry, Biotech Stocks , is 43.97%, which TScan Therapeutics falls below.

Who owns the most shares of TScan Therapeutics?

TScan Therapeutics’s largest shareholders are Lynx1 capital management lp (7.86M shares, 6.06%), Blackrock (4.46M shares, 4.70%), and Ecor1 capital (5M shares, 4.21%). Together, they hold 14.97% of TScan Therapeutics’s total shares outstanding.

Does Blackrock own TScan Therapeutics?

Yes, BlackRock owns 4.70% of TScan Therapeutics, totaling 4.46M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 26.1M$. In the last quarter, BlackRock increased its holdings by 2.76M shares, a 162.61% change.

Who is TScan Therapeutics’s biggest shareholder by percentage of total assets invested?

Dc funds, lp is TScan Therapeutics’s biggest shareholder by percentage of total assets invested, with 36.87% of its assets in 630K TScan Therapeutics shares, valued at 1.15M$.

Who is the top mutual fund holder of TScan Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of TScan Therapeutics shares, with 2.36% of its total shares outstanding invested in 1.34M TScan Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools